At a Glance
- Company: Teva Pharmaceuticals
- Location: United States
- Headline figures: 200+ patents tied to 30+ branded drugs
- Focus area: Patent listings on drug–device products (inhalers, autoinjectors)
- Next steps: FDA delisting process; ongoing FTC scrutiny of Orange Book patents
What happened?
Teva Pharmaceuticals has asked the US Food and Drug Administration to remove more than 200 of its patents from the FDA’s Orange Book. The move follows a Federal Trade Commission (FTC) challenge that argued these listings were improper and anticompetitive.
Why does it matter?
Orange Book listings can trigger automatic 30‑month stays on generic approvals when challenged, so improperly listed patents can delay competition and keep prices high. By delisting these patents, Teva is expected to clear the way for more generic and biosimilar products, potentially lowering drug costs and improving patient access.
Who’s behind it?
The FTC led the challenge, targeting Teva’s patents on more than 30 branded drugs, including asthma and COPD inhalers, diabetes medicines, and epinephrine autoinjectors. The agency argued that many patents covered device components rather than the active drug, and thus did not meet legal criteria for Orange Book inclusion.
How was it achieved?
After the FTC’s challenge and related court rulings, Teva agreed to request removal of the disputed patents from the Orange Book. These patents often covered inhaler mechanisms or autoinjector parts, which the FTC said were being used to extend market exclusivity beyond what patent and drug laws allow.
What’s next?
The FDA will process Teva’s delisting requests, and generic and biosimilar manufacturers could face fewer patent barriers to market entry. The FTC has indicated it will continue monitoring the pharmaceutical industry for other improper Orange Book listings and anticompetitive conduct as part of broader efforts to promote competition and reduce drug prices.
What are people saying?
The FTC has characterised Teva’s decision as a significant victory for its campaign against improper Orange Book listings that delay generic competition. The agency also framed the move as an important step toward lower drug prices and better access to affordable medicines for patients.